As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon

 
• By Mandy Jackson
  
Double escalator going up
CAR-T therapies are moving up from third-line or later into second-line and earlier settings • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D